Search

Author/Creator Turner, N C

1. 289PDLucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. (23rd October 2018)

Authors:
Hui, R; Pearson, A; Cortes Castan, J; Campbell, C; Poirot, C; Azim, H A; Fumagalli, D; Lambertini, M; Daly, F; Arahmani, A; Perez-Garcia, J; Aftimos, P G; Bedard, P; Xuereb, L; Loibl, S; Loi, S; Pierrat, M-J; Turner, N C; André, F; Curigliano, G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. (12th March 2019)

Authors:
Turner, N C; Alarcón, E; Armstrong, A C; Philco, M; López Chuken, Y A; Sablin, M -P; Tamura, K; Gómez Villanueva, A; Pérez-Fidalgo, J A; Cheung, S Y A; Corcoran, C; Cullberg, M; Davies, B R; de Bruin, E C; Foxley, A; Lindemann, J P O; Maudsley, R; Moschetta, M; Outhwaite, E; Pass, M
Journal:
Annals of oncology
Issue:
Volume 30:Number 5(2019)
Page Start:
774
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). (31st January 2019)

Authors:
Condorelli, R; Mosele, F; Verret, B; Bachelot, T; Bedard, P L; Cortes, J; Hyman, D M; Juric, D; Krop, I; Bieche, I; Saura, C; Sotiriou, C; Cardoso, F; Loibl, S; Andre, F; Turner, N C
Journal:
Annals of oncology
Issue:
Volume 30:Number 3(2019)
Page Start:
365
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA2_PROverall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. (23rd October 2018)

Authors:
Cristofanilli, M; Slamon, D J; Ro, J; Bondarenko, I; Im, S-A; Masuda, N; Colleoni, M; DeMichele, A; Loi, S; Verma, S; Iwata, H; Harbeck, N; Loibl, S; André, F; Puyana Theall, K; Huang, X; Giorgetti, C; Huang Bartlett, C; Turner, N C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search